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Abstract
Purpose: Va24-invariant natural killer T cells (NKT) are
attractive carriers for chimeric antigen receptors (CAR) due to
their inherent antitumor properties and preferential localiza-
tion to tumor sites. However, limited persistence of CAR-NKTs
in tumor-bearing mice is associated with tumor recurrence.
Here, we evaluated whether coexpression of the NKT homeo-
static cytokine IL15with aCAR enhances the in vivo persistence
and therapeutic efficacy of CAR-NKTs.
Experimental Design: Human primary NKTs were ex vivo
expanded and transduced with CAR constructs containing an
optimized GD2-specific single-chain variable fragment and
either the CD28 or 4-1BB costimulatory endodomain, each
with or without IL15 (GD2.CAR or GD2.CAR.15). Constructs
that mediated robust CAR-NKT cell expansion were selected
for further functional evaluation in vitro and in xenogeneic
mouse models of neuroblastoma.
Results: Coexpression of IL15 with either costimulatory
domain increased CAR-NKT absolute numbers. However,
constructs containing 4-1BB induced excessive activation-
induced cell death and reduced numeric expansion of
NKTs compared with respective CD28-based constructs.
Further evaluation of CD28-based GD2.CAR and GD2.
CAR.15 showed that coexpression of IL15 led to reduced
expression levels of exhaustion markers in NKTs and
increased multiround in vitro tumor cell killing. Following
transfer into mice bearing neuroblastoma xenografts,
GD2.CAR.15 NKTs demonstrated enhanced in vivo
persistence, increased localization to tumor sites, and
improved tumor control compared with GD2.CAR
NKTs. Importantly, GD2.CAR.15 NKTs did not produce
significant toxicity as determined by histopathologic
analysis.
Conclusions:Our results informed selection of the CD28-
based GD2.CAR.15 construct for clinical testing and led to
initiation of a first-in-human CAR-NKT cell clinical trial
(NCT03294954).
Introduction
Recent clinical trials have demonstrated that T cells expressing
CD19-specific chimeric antigen receptors (CAR) induce sustained
complete responses in patients with B-cell malignancies, leading
to recent FDA approval of CD19-specific CAR T-cell
therapies (1–3). However, clinical results obtained using CAR-
redirected immunotherapy for solid tumors have been largely
disappointing (4, 5).Hence, there is an urgent need for alternative
strategies that improve the efficacy of CAR-mediated cancer
immunotherapy in a wider range of cancers.
CARs can be expressed in T-cell subsets with defined functions.
For instance, CARs have been expressed in cytotoxic T lympho-
cytes (CTL) specific for viral antigens such as those derived from
the Epstein–Barr virus (6). Infusion of CTLs expressing a GD2-
specific CAR (GD2.CAR) derived from the 14G2a monoclonal
antibody to children with neuroblastoma was proven safe and
achieved complete tumor responses in 3 of 11 patients with
refractory/relapsed disease evaluated in one study (7, 8). How-
ever, CAR-CTLs did not effectively infiltrate tumors or persist
in vivo, observations that were associated with tumor recurrence
or lack of objective responses in the majority of patients. An
attempt to increase the affinity of GD2.CAR via mutation of
14G2a single-chain variable fragment (scFv) enhanced antitumor
activity of CAR T cells against neuroblastoma xenografts, but
also produced lethal central nervous system toxicity due to
recognition of low GD2-expressing normal brain cells in
mice (9). New lines of research are examining CAR-based ther-
apies for neuroblastoma and other solid tumors using innate
and innate-like lymphocytes with natural tumor-trafficking and
tumor-targeting properties including NK (10), gd T (11), and
Va24-invariant natural killer T (NKT) cells (12).
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pressing IL15 with an optimized GD2.CAR would enhance the
survival and antitumor effector functions of NKTs within neuro-
blastoma tissues leading to sustained tumor control. Our results
reveal that GD2.CAR constructs encoding 4-1BB, but not CD28,
costimulation triggered excessive activation-induced cell death
(AICD) in NKTs during in vitro expansion. Importantly, coexpres-
sion of IL15 with the GD2.CAR containing the CD28 costimu-
latory endodomain increased the in vivo persistence and antitu-
mor efficacy of CAR-NKTs in metastatic neuroblastoma models
without causing evident toxicity. These preclinical assessments
were instrumental in the implementation of first-in-human
CAR-NKT clinical testing (NCT03294954).
Materials and Methods
Cell lines and culture conditions
CHLA-255, CHLA-136, LA-N-1, and LA-N-6 cell lines were
established and maintained as previously described (15, 22, 23)
and as detailed in Supplementary Methods. 293T cells were
obtained from the ATCC. All cell lines were STR fingerprinted at
MD Anderson Cancer Center within 1 year of use and regularly
validated to be free of Mycoplasma.
NKT cell isolation, expansion, and transduction
NKT cells were isolated from healthy human donor peripheral
blood, ex vivo expanded, and transduced with retroviral vectors
encoding CAR constructs as previously described (24).
CAR constructs and retroviral vector production
SFG retroviral vectors were constructed as previously
described (19) and used to produce retroviral supernatants.
Retroviral supernatants were produced by transfecting 293T
cells with a combination of an anti-GD2 CAR-containing plas-
mid, the RDF plasmid encoding the RD114 envelope, and the
PeqPam3 plasmid encoding the MoMLV gag-pol as previously
described (25). GeneJuice reagent (Novagen) was used to assist
with transfection. Viral supernatants were collected after 48 and
72 hours, filtered with 0.45 mm filters, and frozen.
Flow cytometry
Immunophenotyping was performed using the monoclonal
antibodies (mAb) and reagents detailed in Supplementary Meth-
ods. GD2.CARs were detected with the 14G2a anti-idiotype 1A7
mAb. Analysis was performed on an LSR-II 5-laser flow cytometer
(BD Biosciences) using BD FACSDiva software version 6.0 and
FlowJo 10.1 (Tree Star). SPICE software was used to evaluate the
expression of exhaustion markers (26).
Cytotoxicity assays
Short-term cytotoxicity of parental andGD2.CARNKTs against
CHLA-255, CHLA-136, LA-N-1, and LA-N-6 cells was evaluated
using a 4-hour luciferase assay as previously described (16). The
calcein-AM M2 macrophage cytotoxicity assay was performed as
previously described (27) and detailed in the Supplementary
Methods. For the long-term cytotoxicity assay, GFP-tagged
CHLA-255, CHLA-136, and LA-N-1 cells were plated in a 24-well
plate 1 day prior to adding NKT cells at a 1:1 effector-to-target
ratio. IL2 (50 U/mL) was added every other day. Cells were
quantified by flow cytometry at day 7 based on NKT-invariant
TCR and GFP expression, respectively, with nontransduced NKTs
as negative controls.
Translational Relevance
Chimeric antigen receptor (CAR)–redirected T-cell adoptive
immunotherapy remains largely ineffective in solid tumors
due in part to the limited ability of conventional T cells to
localize to and survive in tumor tissues. In thiswork,we exploit
the intrinsic tumor-trafficking properties of natural killer T
(NKT) cells to home toneuroblastoma tumors and target them
with an engineered GD2-specific CAR coexpressing human
IL15 to enhance CAR-NKT survival. We expressed a set of
optimized GD2-based CAR constructs with either the human
CD28 or 4-1BB costimulatory endodomain—each with or
without IL15—in primary human NKTs and compared the
therapeutic potential and toxicity of resultant CAR-NKTs. The
results of this study informed the design of an ongoing first-in-
human clinical evaluationof CAR-NKT cell therapy in children
with neuroblastoma (NCT03294954).
NKTs are an evolutionarily conserved sublineage of innate-like 
T cells that express the Va24-Ja18 invariant TCR a-chain and are 
characterized by reactivity to self- and microbial-derived glycoli-
pids presented by the monomorphic HLA class-I–like molecule 
CD1d (13). Although the majority of solid tumors are CD1d-
negative, the antitumor potential of NKTs has been demonstrated 
in numerous cancer models (13). We have reported that NKTs 
actively localize to tumors in response to tumor-derived chemo-
kines CCL2 and CCL20 and that the presence of NKTs within the 
primary tumor site is associated with improved outcomes in 
children with neuroblastoma (14, 15). We have also shown that 
NKTs can be isolated from the peripheral blood, transduced with 
CARs, and expanded to clinical scale for adoptive cell therapy 
applications (12, 16).
CD19-specific CAR T cells with either CD28 or 4-1BB endo-
domains have been shown to be effective in patients with B-cell 
malignancies (2). In neuroblastoma patients, a GD2-specific 
CAR containing both CD28 and OX40 endodomains enhanc-
ed CAR T-cell expansion in the peripheral blood compared with 
a CAR without costimulation, but the magnitude of expansion 
was still limited (17). Furthermore, Long and colleagues reported 
that unlike CD19-specific CARs, GD2.CARs undergo tonic sig-
naling resulting from spontaneous dimerization caused specifi-
cally by the 14G2a scFv. This unintended signaling, which led to 
early exhaustion of GD2.CAR T cells, was exacerbated in CARs 
containing the CD28 endodomain and attenuated in CARs con-
taining 4-1BB (18).
We recently described a modified GD2.CAR containing a 
truncated form of the 14G2a heavy chain variable domain that 
despite retaining CD28 induces minimal tonic signaling and 
mediates enhanced antitumor activity in transduced T cells com-
pared with the original GD2.CAR (19). In the same study, we also 
demonstrated that inclusion of IL15 in the optimized construct 
further enhanced the in vitro functionality and in vivo therapeutic 
potency of CAR.GD2 T cells in neuroblastoma models.
Mouse studies and in vitro human experimental models have 
both highlighted the central role of IL15 in NKT cell development 
and homeostatic maintenance (20, 21). Importantly, IL15 pro-
tects human NKTs from hypoxia, and transgenic expression of 
IL15 in adoptively transferred NKTs significantly enhances their 
antitumor activity (15). Therefore, we hypothesized that coex-
2 independent variables were considered. Survival was analyzed
using the Kaplan–Meier method and the log-rank (Mantel–Cox)
test to compare 2 groups. Statistics were computed using
GraphPad Prism 7.0 (GraphPad Software). Differences were
considered significant when the P value was less than 0.05.
Results
Generation and functional testing of NKTs expressing CAR
constructs with or without IL15
We generated retroviral constructs incorporating an optimized
14G2a scFv, human CD8a-derived hinge and transmembrane
domains, a human CD28 (GD2.28z) or 4-1BB (GD2.BBz) costi-
mulatory endodomain, and a human CD3z signaling domain
(ref. 19 and Supplementary Fig. S1A). The cDNA sequence encod-
ing human IL15 was added to GD2.28z (GD2.28z.15) or GD2.
BBz (GD2.BBz.15) CAR constructs following a self-cleaving viral
2A peptide sequence, allowing production of separate peptide
fragments from a single mRNA. Primary human NKTs were
expanded ex vivo following the procedure outlined in Supple-
mentary Fig. S1B and stably transduced with each of the 4
constructs. CAR expression in NKTs was similar for all constructs
as assessed 3 days after transduction (Fig. 1A). NKTs expressing
GD2.28z.15 and GD2.BBz.15 secreted IL15 following a 48-hour
culture without or with GD2-positive CHLA-255 neuroblastoma
cells, with higher levels observed in the latter condition following
NKT activation byCAR engagement (Supplementary Fig. S1C and
S1D).
GD2.28z and GD2.28z.15 NKTs had on average 1.25- and
1.14-fold lower expansion rates than nontransduced (NT) NKTs,
respectively, at day 10 after secondary stimulation (Fig. 1B). GD2.
BBz and GD2.BBz.15 NKT expansion rates dropped to 2.71- and
1.67-fold lower on average than those of NT NKTs, respectively,
and were also significantly lower than those of their respective
CD28-based counterparts (P < 0.0001). When only CAR-positive
cells were considered, IL15 expression increased absolute num-
bers of NKTs expressing both CD28- and 4-1BB–based constructs
(Fig. 1C). Flow cytometry analysis of CAR-NKTs 5 days
after transduction revealed a significantly higher proportion of
early apoptotic cells (annexin-V–positive/7-AAD–negative) in
GD2.BBz NKTs versus GD2.28z NKTs (53.4%  8.8% vs.
25.9%  7.45%, P < 0.01) and in GD2.BBz.15 NKTs versus
GD2.28z.15 NKTs (28.7%  8.14% vs. 8.2%  2.88%, P <
0.05; Fig. 1D and E). Furthermore, 4-1BB-CAR-NKTs expressed
markedly elevated levels of TNF-related apoptosis-inducing
ligand (TRAIL; Fig. 1F) and FAS (Supplementary Fig. S2A) com-
pared with CD28-CAR-NKTs. We also found that all CAR-NKT
groups expressed death receptor TRAIL-R1 (DR4) and to a lesser
extent FASL (Supplementary Fig. S2A and S2B), which together
with TRAIL andFAS, respectively, could lead to self-initiateddeath
receptor signaling in these cells. Indeed, we found higher levels of
death receptor–dependent caspase-8 activity in 4-1BB-CAR-NKTs
than CD28-CAR-NKTs (Fig. 1G). Thus, the 4-1BB costimulatory
endodomain induces AICD, leading to loss of CAR-NKTs
during ex vivo expansion. Instead, NKTs transduced with
CD28-containing GD2.CAR constructs—particularly with
IL15—undergo relatively low levels of AICD and are capable of
extensive numeric expansion, making them a superior option for
generating clinical-scale CAR-NKT cell products. Therefore, we
selected the GD2.28z and GD2.28z.15 constructs for further
preclinical evaluation.
Serial tumor challenge assay
CHLA-255, LA-N-1, and CHLA-136 cells were each cocul-
tured with GD2.28z or GD2.28z.15 NKTs in a 24-well plate 
using fresh culture medium with 50 U/mL IL2. Five days 
later, cells were harvested, quantified using the trypan-blue 
exclusion methods, and analyzed for NKT and neuroblastoma 
cell markers by flow cytometry. CAR-NKT cells were then 
replated at a 1:1 E:T ratio with fresh neuroblastoma cells in 
fresh cell culture medium to start the next round of tumor 
cocultures. At the conclusion of the fourth cycle, NKT cells were 
counted, and the coculture was analyzed by flow cytometry.
Multiplex cytokine quantification assay and ELISA
Culture supernatants of NKTs alone or after 48 hours of 
coculture with CHLA-255 were collected to measure IL15 release 
using the Human IL15 ELISA Kit (R&D Systems). Supernatants 
from in vitro cultures of NKTs with and without CHLA-255 cells 
were collected after 24 hours and analyzed for expression of IFNg , 
IL4, GM-CSF, TNFa, and IL10 using the MILLIPLEX MAP Human 
Cytokine/Chemokine Immunoassay kit (Millipore) for Luminex 
analysis. Mouse IL6 levels in the plasma were determined using 
the mouse IL6 ELISA kit (R&D Systems).
In vivo studies
NSG mice were obtained from The  Jackson Laboratory and  
maintained at the BCM animal care facility. For in vivo per-
sistence experiments, mice were injected intravenously (i.v.) 
with 1  106 CHLA-255 cells. NKTs were cotransduced with 
a GD2.CAR and firefly luciferase using retroviral constructs. 
Seven days after tumor engraftment, approximately 5  106 
CAR-NKTs or control NKTs were injected i.v. into tumor-
bearing mice and monitored using bioluminescent imaging 
every 2 days (Small Animal Imaging core facility, Texas 
Children's Hospital). At the time of euthanasia, blood, spleen, 
liver, lung, and bone marrow were collected, and cells were 
processed for flow cytometry analysis. For in vivo therapeutic 
experiments, mice were injected i.v. with 1  106 firefly lucif-
erase-labeled CHLA-255, CHLA-136, or 2  106 LA-N-1 neu-
roblastoma cells. On day 7, mice were treated with 5  106 
CAR-NKTs followed by intraperitoneal (i.p.) injection of IL2 
(2000 U/mouse) every other day for 2 weeks. Tumor growth 
was assessed twice weekly by bioluminescent imaging. Animal 
experiments were performed according to IACUC-approved 
protocols (BCM IACUC protocol AN-5194).
Immunofluorescent microscopy analyses
Livers of nontransduced, IL15, GD2.28z, and GD2.28z.15 mice 
were cryosectioned, fixed, and immunostained with anti-human 
Va24Ja18 TCR Biotin (clone 6B11, eBioscience), streptavidin 
Alexa Fluor 488 conjugate (Thermo Fisher), and anti-tyrosine 
hydroxylase Alexa Fluor 555 conjugate (clone LNC1, Millipore). 
Slides were costained with ProLong Gold Antifade Reagent with 
DAPI (Thermo Fisher) and images were obtained using an LSM 
780 Confocal Microscope (Zeiss).
Statistical analysis
For in vitro and in vivo experiments, two-sided unpaired or 
paired Student t tests were used to evaluate differences in con-
tinuous variables between two groups. One-way ANOVA with 
posttest Bonferroni correction was used for continuous variables 
among more than 2 groups, and two-way ANOVA was used when
Figure 1.
GD2.CAR constructs containing CD28 costimulatory endodomain enable superior ex vivo expansion of CAR-NKTs. A, Following a 10-day primary
stimulation with a-GalCer–pulsed autologous PBMCs, NKTs were restimulated and transduced 2 days later with the indicated CAR constructs or no construct
(NT: nontransduced). Representative flow cytometry analysis of indicated GD2.CAR construct expression 3 days after transduction by gating on 1A7þ (14G2a
anti-idiotype)/ Va24-Ja18þNKT cells (n¼ 13). B,Quantification of total NKT cell fold expansion, mean SD following 10 days of secondary expansion (n¼ 13).
NKT cell number was determined using the Cellometer Auto Cell Viability Counter with AOPI staining.  , P < 0.05;  , P < 0.0001; NS, not significant; one-way
ANOVA. C, Quantification of CARþ NKT cell expansion calculated following 10 days of secondary expansion. , P < 0.05;  , P < 0.001, Student paired t test.
D, NKTs transduced with the indicated GD2.CAR constructs were stained with annexin V and 7-AAD 5 days after transduction. Shown are representative results
from one of 4 donors. E,Quantification of annexin Vþ/7-AAD- NKTs SD in both CARþ gated and CAR gated populations for indicated GD2.CAR NKT groups
(n¼ 4).  , P < 0.05;  , P < 0.01; NS, not significant; one-way ANOVA. F, TRAIL expression in CARþ gated populations for the indicated GD2.CAR NKTs 7 days
after transduction. Shown are TRAIL median fluorescence intensity (MFI) results from a representative donor and mean SD of TRAIL expression MFI from 6
donors.  , P < 0.001; NS, not significant; one-way ANOVA. G, Levels of activated caspase 8 were evaluated in the indicated CARþ and CARNKT populations
using FAM-LETD-FMK labeling 7 days after transduction. Shown are representative results from one of 3 donors.
Coexpression of IL15 enhances survival and reduces
exhaustion-associated phenotype in GD2.CAR NKTs
Coexpression of IL15 with a CAR construct should provide a
survival advantage for effector cells in the immunosuppressive
tumor microenvironment. To determine whether transgenic IL15
coexpressed with the GD2.CAR mediates this intended effect, we
cultured GD2.28z and GD2.28z.15 NKTs in cytokine-deprived
serum-free medium and evaluated key molecules of the IL15-
mediated prosurvival signaling pathway. We found that
GD2.28z.15, but not GD2.28z, NKTs robustly phosphorylated
Stat5 (Fig. 2A) and upregulated expression of Bcl-2 family mem-
bers Bcl-2 (Fig. 2B) and Bcl-xL (Fig. 2C), indicating that transgenic
IL15 recapitulates the prosurvival functionality of the natural
cytokine.
Next, we examined expression trends for major human NKT
functionalmarkers CD4 andCD62L inGD2.28z andGD2.28z.15
NKTs at the end of in vitro expansion. We confirmed previously
reported interindividual variability in CD4 expression across all
donors tested (28). NKTs from donors with high frequency of
CD4þ cells (80%–100%) retained a high proportion of CD4þ
NKTs after CAR transduction (Fig. 2D). In contrast, NKTs from
donors with low to intermediate levels of CD4 expression (20%–
50%) either decreased or increased the proportion of CD4þ cells
after CAR transduction. We detected a consistent decrease in the
proportion of CD62Lþ NKTs in CAR-transduced versus NT cells,
which is likely due to residual tonic signaling induced by GD2.
CAR, a common phenomenon in the currently used CARs (29).
However, GD2.28z.15 NKTs retained a significantly higher pro-
portion of CD62Lþ cells compared with GD2.28z NKTs in 9 of 11
donors (Fig. 2E). Evaluation of exhaustionmarker levels revealed
that CAR expression led to significant upregulation of PD-1, TIM-
3, and LAG-3 in NKTs (Fig. 2F). However, GD2.28z.15 NKTs
expressed significantly lower levels of PD-1, TIM-3, LAG-3, and
TIGIT (Fig. 2F) and were characterized by significantly fewer cells
positive for three of the exhaustion-associated markers than
GD2.28z NKTs (Fig. 2G). There was no significant difference in
the level of CAR expression observed between the GD2.28z and
GD2.28z.15 NKTs (P > 0.05, paired t test, n¼ 6). The addition of
soluble IL15 to NKT cell culture medium for 7 days after TCR
stimulation similarly reduced PD-1 expression in nontransduced
and GD2.28z NKTs (Supplementary Fig. S3E). Therefore, coex-
pression of IL15 with the GD2.CAR enhances NKT survival and
alleviates the exhaustion phenotype.
Coexpression of IL15 enhances in vitro functional fitness of
GD2.CAR NKTs
To determine the efficacy of CAR-mediated killing byNKT cells,
we cocultured GD2.CAR NKTs with firefly luciferase (Ffluc)-
expressing CD1d-negative and GD2-high (CHLA-255 and
LA-N-1), GD2-medium (CHLA-136), or GD2-negative (LA-N-
6) neuroblastoma cells (Fig. 3A) for 4 hours. NKTs expressing
either GD2.28z or GD2.28z.15 did not kill GD2-negative LA-N-6
cells but mediated equally potent short-term cytotoxicity against
GD2-high neuroblastoma cell lines (Fig. 3B). GD2-medium
CHLA-136 cells were killed less effectively than GD2-high lines
in 4 hours but were eliminated by either GD2.28z or GD2.28z.15
NKTs within 24 hours (Fig. 3C). Although parental NKTs did not
kill CD1d-negative neuroblastoma cells, GD2.CARNKTs retained
their native CD1d-restricted reactivity, as they killed a-galacto-
sylceramide-pulsed M2-polarized macrophages (GD2-negative/
CD1d-positive) as effectively as parental NKTs (Fig. 3D). Next, we
examined changes in GD2.CAR NKT numbers and phenotype
after challenge with neuroblastoma cells. Seven days after adding
any of 3 neuroblastoma cell lines, GD2.28z.15 mediated expan-
sion/survival of significantly higher numbers of NKTs compared
with GD2.28z. However, challenge with CHLA-136 cells resulted
in fewer GD2.CAR NKTs compared with CHLA-255 or LA-N-1
cells (Fig. 3E).
To directly test functional fitness, we cocultured GD2.CAR
NKTs with GFP-transduced neuroblastoma cells for 5 days, then
added equal numbers of the effector cells to fresh tumor cells for
another 5 days and repeated such settings in 4 rounds. At the end
of each round, viableNKT andneuroblastoma cells were analyzed
by flow cytometry (Supplementary Fig. S3A and S3B). We found
that GD2.28z.15 mediated greater NKT cell numeric expansion
after each round compared with GD2.28z (Fig. 3F). Although
NKTs expressing either CAR construct effectively eliminated neu-
roblastoma cells in the first 3 rounds, GD2.28z.15 was more
effective in controlling tumor cell numbers compared with
GD2.28z at the end of the fourth round (Fig. 3G). Flow
cytometry analysis of NKTs after the fourth round revealed
higher levels of PD-1 and TIGIT expression in NKTs transduced
with GD2.28z compared with GD2.28z.15 (Supplementary
Fig. S3C), suggesting that the presence of IL15 in the CAR
construct attenuates NKT cell exhaustion. Similar results were
obtained in a repeat challenge experiment using an IncuCyte
instrument, which allows continuous measurement of viable
tumor cells in coculture with CAR-NKTs (Supplementary
Fig. S3D).
To further evaluate the functional potential of GD2.CARNKTs,
we determined their cytokine production profiles in response to
stimulation with CHLA-255 neuroblastoma cells. GD2.28z and
GD2.28z.15 NKTs both produced high levels of TH1 cytokine
interferon-g (IFNg) in the presence CHLA-255 cells, with levels
approximately 2-fold higher in GD2.28z.15 NKTs (Fig. 3H). Both
groups produced similar levels of TH2 cytokine IL4, resulting in an
overall higher IFNg-to-IL-4 ratio in GD2.CAR NKTs with IL15
(Fig. 3I). Similar trends were observed with TH1 cytokines
GM-CSF and TNFa, while IL10 was not detected from either
GD2.CAR NKT group (Supplementary Fig. S4).
GD2.28z.15 construct supports superior NKT cell in vivo
persistence
Long-term persistence of CAR-effector cells is critical to the
success of adoptive cell therapies (30–33). We examined the
in vivo persistence of GD2.28z and GD2.28z.15 NKTs cotrans-
ducedwithhigh-intensity Ffluc cDNA following transfer intoNSG
mice with 7-day established neuroblastoma xenografts (Fig. 4A).
Mice injected with Ffluc-only and IL15/Ffluc NKTs served as
control groups. Transgenic expression of IL15 on its own
improved NKT persistence compared with NT/Ffluc NKTs while
GD2.28z only marginally boosted persistence above NT/Ffluc
control (Fig. 4B and C). Importantly, addition of IL15 to the
GD2.28z construct significantly enhanced the ability of infused
NKTs to expandandpersist beyond levels seen inGD2.28zor IL15
NKTs. We checked the bone marrow, the primary site of neuro-
blastoma metastases in humans and our mouse model, for the
presence of tumor and NKTs 20 days after NKT cell transfer. Both
IL15/Ffluc and GD2.28z.15 NKT cells were present at approxi-
mately 6 times higher frequency in the bone marrow than NT/
Ffluc NKTs, while GD2.28z NKT frequency did not exceed that of
control NKTs (Fig. 4D). Accordingly, mice treated with
Figure 2.
Coexpression of IL15 enhances survival and reduces exhaustion-associated phenotype in GD2.CAR NKTs. A, Expression of phosphorylated STAT5 (pSTAT5) was
evaluated in NKTs expressing the GD2.28z or GD2.28z.15 CAR 7 days after transduction following 12 hours of culture in serum- and cytokine-starved conditions.
Shown is a representative histogram from one of 4 donors (left) and mean SD of MFI for all donors (n¼ 4).  , P < 0.01, one-way ANOVA. B, Expression of
intracellular Bcl-2 was evaluated in NKTs expressing the GD2.28z or GD2.28z.15 CAR 7 days after transduction following 12 hours of culture in serum- and
cytokine-starved conditions. Shown is a representative histogram from 1 of 4 donors (left) and Bcl-2 expression MFI for each individual donor expressing the
GD2.28z versus the GD2.28z.15 CAR (n¼ 4).  , P < 0.05, Student paired t test. C, Expression of intracellular Bcl-xL was evaluated in NKTs expressing the GD2.28z
or GD2.28z.15 CAR 7 days after transduction following 12 hours of culture in serum- and cytokine-starved conditions. Shown is a representative histogram from 1
of 4 donors (left) and Bcl-xL expression MFI for each individual donor expressing the GD2.28z versus the GD2.28z.15 CAR (n¼ 4).  , P < 0.05, Student paired t
test. D, Following 21-day in vitro expansion, NKTs from 14 individual donors transduced with the indicated constructs or nontransduced (NT) NKTs were
evaluated for CD4 expression and (E) 11 of themwere also examined for CD62L expression by flow cytometry. NS, not significant;  , P < 0.05; , P < 0.01;
 , P < 0.001, Student paired t test. F, NKTs transduced with the GD2.28z or GD2.28z.15 CAR or NT were evaluated for expression of the indicated exhaustion
markers 7 days after transduction (n¼ 8).  , P < 0.05;  , P < 0.01; , P < 0.0001; NS, not significant; one-way ANOVA. G, SPICE analysis of exhaustion marker
expression from 3 of the donors shown in F. Pie charts reflect proportions of indicated NKT groups expressing indicated numbers (0–3) of exhaustion markers.
Colored arcs indicate the specific combinations of exhaustion markers expressed.
GD2.28z.15 NKTs had significantly fewer neuroblastoma cells in
the bonemarrow thanmice treated with GD2.28zNKTs (Fig. 4E).
GD2.28z.15 construct mediates effective infiltration of NKTs
into solid tumor tissues
To control tumor growth, therapeutic effector cells must effec-
tively traffic to the tumor site. Using tumor tissues from neuro-
blastoma nodules in the livers of NSG mice (Fig. 5A), we per-
formed confocal microscopy to evaluate the ability of GD2.CAR
NKTs to infiltrate the tumor 13 days after treatment. Consistent
with previous observations (12, 15), we found that transgenic
expression of either IL15 alone or a GD2.CAR significantly
increased the frequency of NKTs in the tumor tissue as compared
with control NKTs (Fig. 5B and C). GD2.28z.15 NKTs were
present at significantly higher numbers within neuroblastoma
nodules than both GD2.28z NKTs and IL15-only NKTs (Fig. 5B
andC). In addition to the tumor, GD2.28z andGD2.28z.15 CAR-
NKTs were detected in the spleen, liver, bone marrow, and lung
(Fig. 5D). Within these tissues, GD2.28z.15 NKTs were predom-
inantly CD4 compared with GD2.28zNKTs (Fig. 5E), indicating
Figure 3.
Coexpression of IL15 enhances the in vitro functional fitness of GD2.CAR NKTs. A, Flow cytometry analysis of GD2 expression in the indicated neuroblastoma cell
lines. B, The indicated luciferase-transduced neuroblastoma cell lines were cocultured with GD2.CAR NKTs for 4 or (C) 24 hours. Cytotoxicity was calculated by
measuring luminescence intensity of lysed target cells with a plate reader. Shown are results from a representative of 4 experiments (each with a separate NKT
donor) with 3 technical replicates. D, GD2.CAR NKTs were cocultured with calcein-AM–labeled M2-polarized macrophages with or without a-GalCer for 4 hours.
Cytotoxicity was assessed by flow cytometry. Shown are mean SD from 4 donors.  , P < 0.01; NS, not significant; two-way ANOVA. E,NKT cell fold expansion
measured after 1:1 coculture with neuroblastoma cells for 7 days with 50 U/mL IL2. NKT cell number was determined using the cell counter and flow cytometry.
Shown are mean SD from 4 donors.  , P < 0.05;  , P < 0.01, Student unpaired t test. F,Neuroblastoma cells expressing GFP were plated at a 1:1 effector-to-
target (E:T) ratio with GD2.CAR NKTs every 5 days for 4 cycles. NKT cells were harvested from the previous coculture and then replated in new culture medium
with fresh tumor cells at the same 1:1 E:T ratio. At each cycle, cells were counted and analyzed by flow cytometry. Shown are results of a representative cell line,
CHLA-255, from one of 2 independent experiments performed with 3 NKT donors per experiment.  , P < 0.05;  , P < 0.01;  , P < 0.001, Student paired t test. G,
Tumor cells remaining after cycle 4 following the experiment described in F.  , P < 0.05;  , P < 0.001, Student paired t test. H,GD2.CAR NKTswere stimulated
with CHLA-255 cells or left unstimulated and supernatants were collected at 24 hours. IFNg concentrations were measured by Luminex assay. Shown are mean
SD from a representative of 3 experiments with 3 technical replicates.  , P < 0.001, two-way ANOVA. I, Ratio of IFNg-to-IL4 production by GD2.CAR NKTs
following 24-hour coculture with CHLA-255 cells. Shown are mean SD for 3 donors with 3 replicates each.  , P < 0.001, Student unpaired t test.
effectively home to and persist in tumor tissues, in particular due
to increased survival and/or expansion of the CD4 subset with a
possible exception for donors with a high proportion of CD4þ
NKTs.
GD2.28z.15 construct enables superior therapeutic activity of
GD2.CAR NKTs in mice without significant toxicity
We next evaluated the ability of GD2.CAR NKTs to control
tumor growth in 3 xenogeneic neuroblastomamodels. NSGmice
were intravenously injected with CHLA-255, LA-N-1, or CHLA-
136 neuroblastoma cells stably expressing Ffluc, and 7 days later
they received 5  106 of either GD2.28z or GD2.28z.15 NKTs
intravenously (Fig. 6A). Mice treated with NT or IL15-transduced
NKTs were used as control groups. We found that GD2.28z.15
Figure 4.
The GD2.28z.15 construct supports superior NKT cell in vivo persistence. A,Overview of in vivoNKT persistence experiments. NSGmice were injected
intravenously with CHLA-255 neuroblastoma cells followed 7 days later by luciferase-labeled CAR.GD2 or control NKTs. NKTs were tracked by bioluminescence
imaging every 2 to 3 days. B, Bioluminescent monitoring of NT, IL15, GD2.28z, and GD2.28z.15 NKTs injected into groups of mice (n¼ 8/group) carrying CHLA-
255 xenografts. Shown are representative results from one of 3 experiments (each with a separate NKT donor). C,Quantification of bioluminescence images in B.
 , P < 0.001, GD2.28z versus GD2.28z.15, Student unpaired t test. D,Quantification of NKT cells (human CD45þ/NKTþ) in total bone marrow cells at day 20 as
determined by flow cytometry. , P < 0.05;  , P < 0.01, one-way ANOVA. E,Quantification of neuroblastoma tumor cells (human CD56þ/GD2þ) in total bone
marrow cells at day 20 as determined by flow cytometry. Five mice in both NT and IL15 groups were granted exceptions to delay euthanasia until day 20, but
could not be imaged on day 18.  , P < 0.05;  , P < 0.01; NS, not significant; Student unpaired t test.
that local IL15 production preferentially benefits survival and/or 
expansion of CD4 over CD4þ NKTs. CD62L expression was 
generally low in GD2.CAR NKTs infiltrating the tissues regardless 
of transgenic IL15 (Fig. 5F). At the later time point (8 weeks) after 
infusion, CAR-NKTs could still be found in bone marrow at the 
frequencies of 6.26%  1.006% and 0.026%  0.003% for 
GD2.28z.15 and GD2.28z, respectively (Fig. 5G; P < 0.001). 
Again, these long-term persisting GD2.28z.15 NKTs were prefer-
entially CD4 cells in 3 experiments from NKT cell donors with 
20%–50% CD4þ NKT frequency in peripheral blood (Fig. 5H). 
However, GD2.28z.15 NKTs from one donor with a high pro-
portion of the CD4þ subset at baseline still exhibited increased 
persistence in bone marrow while retaining CD4 expression 
(Supplementary Fig. S5A and S5B). Therefore, GD2.28z.15 NKTs
Figure 5.
GD2.28z.15 mediates effective infiltration of NKTs into solid tumor tissues and expansion of CD4-negative NKTs.A, CHLA-255–bearing NSGmice were injected
with luciferase-labeled GD2.CAR or control NKTs in a similar experimental setup as shown in Fig. 4A. Thirteen days after injection of NKTs, resected livers were
photographed. Shown are representative images from 5mice per group, 1 of 3 experiments. B, Liver metastases from Awere fixed and processed for
cryosectioning. Sections were probed with antibodies against the Va24-Ja18 NKT TCR, neuroblastoma tumor marker tyrosine hydroxylase, and DAPI. Images
were visualized and quantified by confocal microscopy. C,Absolute numbers of NKT cells and tumor cells were counted in 10 fields per mouse using images in
B, 5 mice per group.  , P < 0.01;  , P < 0.0001; NS, not significant; one-way ANOVA.D,Quantification of human NKT cells (human CD45þ/NKTþ) in total cell
populations collected from indicated organs (n¼ 5), 1 of 3 experiments.  , P < 0.01;  , P < 0.001;  , P < 0.0001; NS, not significant; one-way ANOVA.
E,Quantification of CD4þNKT cells in total cell populations collected from indicated organs (n¼ 5). , P < 0.05;  , P < 0.001;  , P < 0.0001; NS, not
significant; one-way ANOVA. F,Quantification of CD62LþNKT cells in total cell populations collected from indicated organs (n¼ 5).  , P < 0.05; NS, not
significant; one-way ANOVA. G, At week 8 after injection, human NKT cells were quantified in total cell populations collected from bonemarrow (n¼ 4).
 , P < 0.001, Student unpaired t test. H,Quantification of CARþ, CD4þ, or CD62Lþ subsets of NKT cells in bone marrow as in G (n¼ 4). Data from a
representative of 3 independent experiments.  , P < 0.05;  , P < 0.001; NS, not significant; Student unpaired t test.
Figure 6.
GD2.28z.15 enables superior in vivo therapeutic activity of GD2.CAR NKTs without causing significant toxicity. A, Schematic representation of in vivo tumor
challenge experiments. NSGmice were injected intravenously with luciferase-labeled neuroblastoma cell lines followed 7 days later by CAR.GD2 NKTs. Tumor
growth was assessed weekly by bioluminescence imaging. B,Weekly bioluminescent monitoring of CHLA-255 tumor growth in mice (n¼ 7/group). C, Kaplan–
Meier curve generated from survival of animals in B.  , P < 0.001 log-rank (Mantel–Cox). D,Quantification of bioluminescence in B. E,Weekly bioluminescent
monitoring of CHLA-136 tumor growth. F, Kaplan–Meier curve generated from survival of animals in E.  , P < 0.001 log-rank (Mantel–Cox). G,Quantification of
bioluminescence in E. H,Weekly bioluminescent monitoring of LA-N-1 tumor growth. I, Kaplan–Meier curve generated from survival of animals in H.  , P < 0.01
log-rank (Mantel–Cox). J,Quantification of bioluminescence in H. Shown are representative results from 1 of 4 independent experiments with the CHLA-255
model and one experiment each for the CHLA-136 and LA-N-1 models.
neuroblastoma tumors. Our results demonstrate that NKTs
expressing either GD2.28z or GD2.28z.15, but not GD2.BBz or
GD2.BBz.15, CAR constructs can be expanded ex vivo to clinical
scale and mediate potent CAR-dependent killing of neuroblas-
toma cells in vitro. Compared with GD2.28z, GD2.28z.15 CAR-
NKTs demonstrated superior functional fitness, prolonged in vivo
persistence, and superior tumor control in mice without causing
significant toxicity.
When comparing GD2.CAR constructs incorporating the 2
most commonly used costimulatory endodomains, CD28 and
4-1BB, we found that 4-1BB–containing constructs induced
higher levels of AICD in NKTs than CD28-containing constructs,
regardless of IL15 coexpression. This AICD was associated with
increased TRAIL and FAS expression, activation of caspase-8,
and induction of apoptosis, resulting in lower overall NKT cell
numeric expansion. In line with our findings inNKTs,Mamonkin
and colleagues observed that 4-1BB–containing CARs expressed
from a retroviral vector with strong LTR promoter activity
enhanced AICD levels in transduced T cells (35). Specifically,
4-1BB–mediated TRAF-dependent NFkB activation led to upre-
gulation of death receptors and an increased rate of AICD in
CAR T cells.
Although GD2.28z and GD2.28z.15 NKTs were equally
effective in short-term cytotoxicity assays against 2 GD2-high
(CHLA-255 andLA-N-1) neuroblastoma cell lines, bothmediated
reduced cytotoxicity against GD2-medium (CHLA-136) neuro-
blastoma cells. CHLA-255 is an MYCN-nonamplified line while
LA-N-1 andCHLA-136 areMYCN-amplified lines, suggesting that
the efficacy of CAR.GD2 NKT cell therapy depends on the level of
GD2 expression on neuroblastoma cells rather than their MYCN
status. GD2.28z.15 NKTs demonstrated significantly more effec-
tive tumor control in a repeat challenge assay. This activity was
associatedwith expansion ofGD2.28z.15 but notGD2.28zNKTs.
We recently showed parallel results with T cells expressing the
same 2 constructs; GD2.28z.15 T cells demonstrated superior
expansion and antitumor activity after numerous tumor cell
exposures compared with GD2.28z T cells (19). Additionally, we
have found that expression of IL15-containing CARs is associated
with reduced exhaustion marker expression in both T and NKT
cells, suggesting that IL15 prevents NKT cell exhaustion in the
same manner as it does in T cells.
Coexpression of IL15 with the GD2.CAR enriched for T cells
with memory and stem-cell–like phenotypes (19). Although the
mechanisms governing memory differentiation of human NKTs
remain less explored than those of T cells, we recently demon-
strated that CD62Lþ central memory–like NKTs can expand in
culture and are largely responsible for the in vivo persistence and
therapeutic potential of CAR-NKTs (16). The addition of IL15 to
the CAR increased the frequency of CD62Lþ NKTs in 9 of 11
donors examined, suggesting that IL15 protects NKTs from cell
death and exhaustion, and may provide a selective advantage for
central memory-like NKTs.
After adoptive transfer to tumor-bearing mice, GD2.28z.15
NKTs demonstrated remarkable persistence especially in the bone
marrow and liver (primary sites of neuroblastoma metastasis)
despite the highly hypoxic microenvironment of neuroblastoma
livermetastases that hampers NKT survival and function (15).We
previously reported that transgenic IL15 protects NKTs from
hypoxia (15), and here we further observed that IL15 promotes
survival of CAR-NKTs in neuroblastoma xenografts in the liver.
Furthermore, phenotypic analysis of infiltrated CAR-NKTs
NKTs controlled tumor growth significantly longer than GD2.28z 
NKTs in all three neuroblastoma models (P < 0.001; Fig. 6B–J). 
The GD2.28z.15 NKT cell therapy was particularly effective 
against xenografts of 2 neuroblastoma cell lines with high-level 
GD2 expression, mediating prolonged survival of the majority of 
mice without evidence of disease up to three months postinfusion 
when animals were sacrificed. We also treated CHLA-255 tumor–
bearing mice with a lower (2  106) or a higher (107) dose of CAR-
NKTs. Supplementary Fig. S6 demonstrates that NKTs expressing 
the IL15-containing CAR retain superior antitumor activity at a 
low and a high dose. Moreover, only GD2.28z.15 NKT therapy 
mediated long-term disease-free survival in the majority of mice 
at the high dose. Thus, consistent with its ability to mediate the 
longest duration of in vivo persistence and most effective tumor 
infiltration, GD2.28z.15 also imparted NKTs with superior dose-
dependent antitumor activity, especially against tumors with 
high-level GD2 expression.
We observed mild hunched mouse stature and ruffled fur 
12 days after injection of GD2.28z.15 NKTs that completely 
resolved within 2 to 3 days. At approximately the same time, 
transient weight loss not exceeding 10% of total body weight also 
occurred (Supplementary Fig. S7A). Beyond day 14, animals 
maintained or increased weight. Serum collected on days 12 and 
15 was analyzed by ELISA for the presence of human IL15 and 
murine IL6, the latter of which is produced predominantly by 
murine macrophages in a manner that parallels the development 
of cytokine release syndrome in humans (34). Murine IL6 levels 
were not significantly different between GD2.28z.15 NKT-treated 
and untreated control mice (Supplementary Fig. S7B), while 
human IL15 remained undetectable in both groups. Detailed 
pathologic examination was also performed by an experienced 
clinical pathologist in mice sacrificed at day 12 or 15 after NKT 
injection. Lung, heart, liver, spleen, kidney, adrenals, stomach, 
intestine, pancreas, spine, brain (cerebrum, hippocampus, and 
cerebellum), skin, bone with bone marrow, and skeletal muscle 
revealed minimally detectable tumor cells in 2 mice. Additionally, 
no pathologic abnormalities were detected in any organ or tissue 
with the exception of the lungs, where mice in both groups 
exhibited signs of focal minimal-to-mild interstitial inflamma-
tion. An additional long-term tissue evaluation performed 
between 45 and 60 days after injection of GD2.28z.15 NKTs 
also showed complete absence of toxicity or features of graft-
versus-mouse disease (Supplementary Fig. S7C). There was also 
no tissue toxicity observed including in the brains of mice treated 
with 107 GD2.28z.15 NKTs (Supplementary Fig. S8). Thus, 
GD2.28z.15 NKTs exert potent anti- neuroblastoma activity with-
out causing significant off-target toxicity in mice.
Discussion
NKTs are a promising cellular platform for CAR-redirected 
cancer immunotherapy. Our previous studies have demonstrated 
that NKTs naturally traffic to neuroblastoma in xenograft models 
in response to tumor-derived chemokines and that their ability to 
infiltrate tumors is further enhanced by expression of a tumor-
specific GD2.CAR (12, 15).
We have also found that NKT cell functionality is inhibited in 
the hypoxic tumor microenvironment and at least in part rescued 
by the transgenic expression of IL15 (15). Therefore, we sought to 
test the hypothesis that coexpression of IL15 with the GD2.CAR 
would enhance the ability of NKTs to traffic to and attack
revealed enrichment of NKTs expressing low levels of CD62L,
suggesting that persistent CAR stimulation promotes effector
memory–like differentiation of NKTs as occurs in T cells.
NKTs produce numerous cytokines, which individually may
exert either proinflammatory or inhibitory effects. Our in vitro
testing showed that NKTs coexpressing IL15 and a GD2.CAR
predominantly secrete a TH1-like profile following CAR engage-
ment as evidenced by increased production of IFNg , GM-CSF, and
TNFa aswell as an increased IFNg-to-IL4 ratio. This observation is
consistent with our previous findings showing higher expression
of the IL2Rb/IL-15Rb subunit (CD122) in CD4 NKTs (21),
which produce more TH1 and less TH2 cytokines than CD4
þ
NKTs (28). Moreover, in murine models, CD4 NKTs have been
reported to have better antitumor functionality in vitro and in vivo
compared with their CD4þ counterparts (36). Despite increased
sensitivity of CD4 NKTs to IL15, we did not observe consistent
changes in CD4þ/CD4 proportion during in vitro expansion of
GD2.28z and GD2.28z.15 NKTs, likely due to the presence of IL2
in culture medium. In contrast, after adoptive transfer to tumor-
bearing mice, GD2.28z.15 NKTs derived from 3 donors with low
to intermediate levels of CD4þ cells persisted predominantly as
CD4 cells within the tumor. We did observe, however, that
GD2.28z.15 NKTs derived from a donor with a high proportion
of CD4þ NKTs retained CD4 expression in vivo, a phenomenon
that needs to be further explored.
We found that the potent antitumor effect of GD2.28z.15NKTs
occurred without significant toxicity. The pathologic analysis of
mouse tissues including brain did not reveal signs of inflamma-
tion. In contrast, Richman and colleagues observed lethal CNS
toxicity when testing T cells expressing a mutated CAR.GD2 with
an increased affinity to GD2 (9), indicating that increasing CAR
affinity to GD2 may not be a viable strategy for increasing the
therapeutic efficacy of GD2-targetting immunotherapy. Instead,
our approach is based on enhancing functionality of the CAR-
expressing effector cells that leads to enhanced antitumor activity
without evident toxicity to normal tissues. In contrast, systemic
administration of IL15 in patients with cancer has been associated
with dose-limiting toxicities (37), although IL15/IL15Ra super-
agonists such as ALT-803 show an increased therapeutic index in
the initial clinical testing (38). IL15 remained undetectable in the
serum of mice treated with GD2.28z.15 NKTs, indicating that the
therapeutic effects of IL15 are likely associatedwith local release of
the cytokine at the tumor site.
Basedon results of a randomizedphase III clinical trial (39), the
FDA approved anti-GD2 monoclonal antibody ch14.18 (dinu-
tuximab) in combination with GM-CSF, IL2, and 13-cis-retinoic
acid for maintenance therapy of high-risk neuroblastoma. The
antitumor activity of dinutuximab largely depends on antibody-
dependent cellular cytotoxicity (ADCC),which ismediated byNK
and myeloid cells and augmented by IL2 and GM-CSF, respec-
tively (40, 41). Ch14.18 given as a single agent is ineffective (42).
Although the role of individual cytokines in this combination
therapy is still under investigation, the current regimen remains
toxic and not curative for a third of high-risk patients (43).
GD2.28z.15 NKT cell therapy is designed to maximize direct
neuroblastoma cell killing without dependence on ADCC or
systemic cytokine administration thatmay lead to amore effective
and safe immunotherapy for high-risk and relapsed
neuroblastoma.
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